PROGRAM GUIDE

20TH CIMT ANNUAL MEETING

MAY 3-5, 2023

Rheingoldhalle Congress Center
Mainz, Germany

20TH CIMT ANNUAL MEETING

CONTENT

INTRODUCTION

DEAR COLLEAGUES, MEMBERS AND FRIENDS,

Welcome to the 20th CIMT Annual Meeting!

In 2003, we met here in Mainz for the first time for a dedicated European cancer immunotherapy meeting. The field occupied an academic niche with high hopes of finding better therapies for cancer patients. We knew we needed to better understand the complex biology of cancer and its interplay with the immune system. We also knew we needed to discuss our research with colleagues from around the world, and that it was crucial to bring together the researchers with the developers. Every year since then, except for 2020, the CIMT Annual Meetings have connected not only the European but also the international cancer immunotherapy community with participants attending from over 30 countries.

In the last twenty years, we have seen many advances in our understanding of the mechanisms of the immune system and also many successes transferring this knowledge into clinical practice. Major therapeutic strategies have been validated and approved. Checkpoint inhibitors now rescue the lives of numerous patients. In the last five years, the research field of cancer immunotherapy has further diversified with investigations of the microbiome, of metabolomics, and our ability to draw immunological insights leveraging machine learning and artificial intelligence.

CIMT has always been interested in bringing together different generations of immunologists, facilitating a dynamic dialogue that inspires the future leaders of the field. With our Short Talk session format, early-career researchers present their research to large audiences of experts. Our stipends for travel to the CIMT Annual Meeting support early-career researchers from underrepresented countries.

On behalf of the CIMT board and the CIMT organizational team, I would like to express our gratitude to our industry partners and sponsors for their continued and generous support. Without them, CIMT would not have been able to organize meetings of this scope and scale.

I wish you a rewarding conference with many inspiring sessions and discussions.

Yours sincerely,

Özlem Türeci
CIMT President

THE ASSOCIATION

WHO WE ARE

The Association for Cancer Immunotherapy CIMT was founded in 2002 as an information and education platform for the emerging field of immunological cancer therapy. Physicians and researchers from different fields of clinical and theoretical medicine were the founding members of the association. CIMT has since become the leading European communication platform for all aspects of science and translation in the field of cancer immunotherapy. CIMT operates as an independent non-profit organization in Mainz, Germany, and is financed by donations, sponsoring, and congress fees.

Our Goals

CIMT promotes the development of cancer immunotherapies by

- offering a platform for knowledge exchange between scientists of all faculties interested in cancer immunotherapy. CIMT connects industry-based scientists, academic scientists, regulatory authorities and physicians alike.
- cooperating internationally with partners in related consortia, regulatory agencies, journals, academic institutions and companies.
- initiating working groups that actively accelerate the development in the field.
- organizing annual meetings, advanced education seminars, symposia, workshops, and by publishing guidelines and textbooks.

2023 PROGRAM COMMITTEE:

ANNUAL MEETING

SPONSORS

In 2023, the CIMT Annual Meeting is supported by the following industry leaders:

Platinum

Gold

Silver

Supported by

ANNUAL MEETING

GENERAL MEETING INFORMATION

INTERNET

Wireless Internet is available throughout the Rheingoldhalle Congress Center. The password for login is: **CIMT2023**. To ensure everyone has access, please only connect one device at a time.

CONFERENCE APP

Scan the QR code on page 11 and follow instructions for iOs and Android.

SPEAKER PREPARATION AREA

Plenary and Short Talk speakers must visit the Speaker Preparation Desk at least two hours prior to their session to load presentations and confirm presentation order. The desk is situated to the left of the registration counter.

POSTER EXHIBIT

Posters are displayed throughout the length of the conference. During their poster sessions, presenters are asked to be present at their poster boards for discussion with delegates.

Please note that one category of Poster Session II will take place at the lower Rheinfoyer, downstairs from the Industry Exhibit. The lower floor is also accessible by elevator at the far end of the Industry Exhibit.

SOCIAL MEDIA

We invite all attendees to follow the conference on Twitter **@C_IMT** and use the hashtag **#CIMT2023** for this conference.

While we encourage your use of social media in and around the conference, we ask that you be aware of the following guidelines:

You are welcome to discuss the conference and what you are hearing and seeing, but please refrain from sharing raw and unpublished data presented. Follow journal rules about data sharing and the general copyright and image rights of the conference.

While engaging in conversations, please be tolerant of differences of opinion you may encounter. Keep criticism constructive.

POSTER AWARDS

At the meeting, all poster entries will be judged by an international judging panel to select the 2023 Poster Award winners who will be announced on May 5, right before Plenary Session 6.

Poster Award winners will be contacted beforehand via email.

SOCIAL EVENT

The CIMT Social Event will take place on May 4, 7:30-11:00 p.m.

Venue Address:
Altes Postlager, Mombacher Str. 11-15, 55122 Mainz

Please ask the registration desk for availability and additional information.

COPYRIGHT AND IMAGE RIGHTS

We ask to limit photography at the congress halls. The use of other recording or transmission devices on site or online is prohibited. By participating in this conference, you agree to our copyright and image rights:

1. Posters, graphics, lectures are usually protected by international copyright laws. Each lecturer warrants that they hold the rights of use to the items used during their lecture (texts, photographs, graphics).
2. It is not permitted without express prior authorization by the author(s) to take pictures of posters, graphics, people, etc., and to transfer these pictures to third parties via social media (Facebook, Twitter,....) or webpages. The person taking the pictures must be able to provide proof of such authorization by the author(s) (e.g. author's mail). Protected material may only be used if the author(s) is mentioned by name.
3. Each participant agrees to indemnify CIMT against any claims for damages by third parties arising from the infringement of any rights by the participant.
4. Each participant agrees to allow CIMT to take pictures of them during the event, and they agree to the use of such pictures for CIMT advertising purposes (Internet,...) and press releases.

CONFERENCE CATERING

Your conference ticket includes snacks, drinks, and lunches during all three conference days.

ADDITIONAL POLICIES AND PROCEDURES

- The Rheingoldhalle Congress Center is 100% smoke-free.
- Children under 12 years of age are not permitted in any scientific session or poster session at any time. Children cannot be left unattended or unsupervised.
- Cell phones, pagers, and other electronic devices must be turned off or placed on "silent" mode before entering a session.
- Lost and Found: Attendees may contact the conference registration desk for any lost items.
- Poster presenters are solely responsible for placing their poster on the assigned poster board and removing their poster according to the schedule provided. The conference organizers cannot be held responsible for any posters that are not removed at the designated time. Posters left after that time may be discarded.
- Poster presenters should not leave any items at their poster board unattended, including poster tubes, meeting bags, programs, personal items, etc. The conference organizers are not responsible for lost items.

CERTIFICATES OF ATTENDANCE & RECEIPTS

A certificate of attendance is sent to each attendee after the conference.

CONTACT

During the meeting, you can reach us by mail at info@wikonect.de or by calling +49 151-53 222 559.

ANNUAL MEETING

WEBSITES

visit our websites
www.cimt.eu & www.meeting.cimt.eu

follow us on twitter
www.twitter.com/C_IMT
#CIMT2023

ONLINE ABSTRACTS

download all abstracts in PDF format at
www.meeting.cimt.eu/speakers-and-program

follow us on LinkedIn
www.linkedin.com/company/cimt

CONFERENCE APP

To download the conference app, scan the QR code, then follow these instructions for your mobile operating system.

iOS

1. Click on the icon for *sharing*.
2. A menu window will open. Scroll down until you see the "*Go to Home Screen*" option.
3. Select "*Add to Home Screen*".
4. Confirm the installation by clicking on "*Add*".
5. Re-open the Congress app via the icon on the home screen.

Android

1. A menu window will open saying "*Add this app to your Home Screen*".
2. Confirm the installation by clicking on "*Install*".
3. Re-open the Congress app via the icon on the home screen.

Looking for a physiologically relevant model?

ATCC®

LGC

Advanced cell models from ATCC

- hTERT Immortalized Cells
- Cancer Organoids
- Primary Cell Solutions
- EMT & MET Reporter Cells
- Luciferase Reporter Cells
- Isogenic Cell Lines

Come visit us for more information at Booth #29

ANNUAL MEETING

PLENARY SPEAKERS

Rafi Ahmed

Emory University
Atlanta, United States of America

Rafi Ahmed is Director of the Emory Vaccine Center at Emory University School of Medicine in Atlanta, USA and a Georgia Research Alliance Eminent Scholar. His research efforts are directed towards: 1. Understanding the mechanisms of immunological memory and using this knowledge to develop new and more effective vaccines. 2. Defining the mechanisms of T-cell exhaustion and developing effective immunotherapy for treatment of cancer and chronic viral infections. Rafi Ahmed is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences.

Vinod Balachandran

Sloan Kettering Cancer Center
New York City, United States of America

Vinod P. Balachandran is a surgical oncologist who specializes in treating people with both benign and cancerous diseases of the pancreas, bile duct, gallbladder, and liver. He is Assistant Member of the Immuno-Oncology Service of the Human Oncology and Pathogenesis Program (HOPP), an Assistant Attending Hepatopancreatobiliary Surgeon in the Department of Surgery, and Member of the Rubenstein Center for Pancreatic Cancer Research. His clinical and laboratory focus is to discover new immunotherapies for pancreatic cancer by studying a highly rare subgroup of pancreatic cancer patients that, remarkably, survive long-term. His aim is to discover the underlying immunological principles at play in these patients, and to translate these principles into new clinical immunotherapies.

Sebastian Amigorena

Institut Curie
Paris, France

Sebastian Amigorena is the head of the Immunology Department (INSERM U932, "Cancer Immunity") at the Curie Institute. Sebastian Amigorena's main scientific interest overlaps immunology and cell biology. In his graduate and post-doctoral studies, he analyzed the functions of IgG receptors and described the molecular basis of their inhibitory properties. Sebastian Amigorena is today an expert in antigen presentation and cross presentation in dendritic cells. He analyzed dendritic cells' endocytic and phagocytic pathways and described several unique specializations of both pathways. Sebastian Amigorena and his team also made significant contributions to the analysis of cytotoxic T-cell dynamics in vivo, during the initiation of immune responses in lymph nodes and during the invasion and rejection of solid tumors. More recently, he contributed to understanding the epigenetic programing of T-cell memory and studied a new category of epigenetically regulated tumor antigens.

Adelheid Cerwenka

UMM Mannheim
Mannheim, Germany

Adelheid Cerwenka has long-standing expertise in the biology of Innate Immunity, in particular Natural Killer (NK) cells and other Innate Lymphocytes. She studied pharmacy in Vienna, Austria followed by a PhD in Immunology. After a post-doc at the Trudeau Institute, NY, USA, she joined the Laboratory of Prof. Lewis Lanier at DNAX and UCSF, SF, USA. In 2001, she took a position at Novartis, Vienna, and in 2003, she was recruited as junior group leader to the German Cancer Center in Heidelberg. Since 2017, she has been full professor and chair of immune-biochemistry at Heidelberg University, where she was elected Vice Dean of Research. She also serves as director of the Mannheim Institute for Innate Immunoscience (MI3).

George Coukos

Ludwig Institute for Cancer Research
Lausanne, Switzerland

George Coukos is a leading investigator in the field of tumor immunology and ovarian cancer. He is interested in elucidating fundamental mechanisms in the tumor microenvironment (TME) that determine the fate of antitumor immunity, focusing on the study of the deregulation of tumor-infiltrating lymphocytes (TILs). These studies are expected to yield novel pharmacologic approaches to restore antitumor immunity as well as novel methodologies to select and expand TILs for adoptive therapy. He is also involved in the study of the tumor vasculature as a barrier to effective T-cell infiltration in many tumors, but also as a potential target for therapy. He pursues T-cell engineering approaches as a means to address the deregulation of T-cells in the TME, and to redirect them against relevant tumor targets, including the vasculature.

Guoliang Cui

HI-TRON and German Cancer Research Center DKFZ
Mainz and Heidelberg, Germany

Guoliang Cui received his Ph.D. at the Shanghai Institute for Biological Sciences (SIBS) in 2010. He finished his postdoc training with Professor Susan Kaech at Yale University in 2016 and was recruited by the German Cancer Research Center (DKFZ) in Heidelberg to start his laboratory in 2016. He has been tenured Head of Division since 2021 at HI-TRON Mainz. Guoliang Cui has received several awards, including the Helmholtz Young Investigator Award (2016), Georges-Köhler Prize (2020), EMBO Young Investigator Award (2021), Lloyd J. Old STAR Award (2021), and ERC consolidator grant (2022).

Feline Dijkgraaf

Cancer Cell
Amsterdam, The Netherlands

Feline Dijkgraaf obtained her M.S. in Medical Biology at the University of Amsterdam in the Netherlands. She performed her Ph.D. research in the laboratory of Dr. Ton Schumacher at the Netherlands Cancer Institute (NKI), where she studied the formation and function of tissue-resident memory T-cells. In parallel, she worked as a Science Communicator on the NKI Cancer Immunotherapy communication program together with Dr. John Haanen. She then joined Elsevier as an internal Scientific Editor for Elsevier's Oncology Journal Network from the Amsterdam office, and subsequently worked as a Scientific Managing Editor on the Cell Press transfer team. Feline joined Cancer Cell in spring 2022, where she is working toward a strong cancer (immunotherapy) portfolio covering basic, translational, and clinical research.

Stefan Fröhling

German Cancer Research Center DKFZ and NCT Heidelberg
Heidelberg, Germany

Stefan Fröhling is Head of the Translational Medical Oncology Division at the German Cancer Research Center (DKFZ) and Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg. His work at the interface of applied cancer research and clinical care centers on strategies for multidimensional tumor characterization, investigating the efficacy of novel, individualized cancer therapies. In addition to his work in the field of cross-entity precision oncology, he focuses on translating insights on the biology of bone and soft-tissue sarcomas and myeloid malignancies into novel diagnostic and therapeutic strategies. He coordinates the Research Platform "Cancer Genome Analysis" of the German Cancer Consortium (DKTK) and the DKFZ/NCT/DKTK MASTER Program to implement genetically guided precision oncology into standard care in Germany.

John Haanen

The Netherlands Cancer Institute
Amsterdam, The Netherlands

John Haanen focuses on the development of cellular therapies for solid tumors, neo-adjuvant immunotherapies, and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer and management of immune-related adverse events. After training in internal medicine, he did a post-doctoral fellowship at the Division of Immunology of the Netherlands Cancer Institute in Amsterdam, where his research focused on the development of innovative immunotherapies in close collaboration with Ton Schumacher. In 2008, he was appointed professor of translational immunotherapy of cancer at Leiden University Medical Center. From 2009 until 2018, he headed the Division of Medical Oncology at NKI and in 2018 was appointed CSO Immunotherapy. He is currently Editor-in-Chief of ESMO IOTECH.

Niels Halama

German Cancer Research Center DKFZ
Heidelberg, Germany

Niels Halama is head of the department of translational immunotherapy at the German Cancer Research Center (DKFZ) and an attending oncologist at the department of Medical Oncology (National Center for Tumor Diseases) with a focus on gastrointestinal solid tumors. His main interests include pioneering novel immunotherapies harnessing the (innate) immune system as well as developing tissue processing workflows, human model systems, and new computational algorithms for (image) data processing. These workflows and highly diverse technologies are being applied in translational projects with implementation in clinical trials. Niels Halama is a board-certified medical oncologist, and has also worked in software development for engineering companies.

Julie Helft

Institut Cochin - INSERM
Paris, France

Julie Helft leads the "Phagocyte and Cancer Immunology" lab at Institut Cochin in Paris and co-directs the "Cancer" scientific axis of the institute. Her lab focuses on deciphering the cross-talks between phagocytes and the tumor microenvironment. In particular, the lab studies the role of macrophage subsets in regulating CD8+ T-cell infiltration and activation within tumors. The lab also studies the mechanisms underlying the systemic accrual of myeloid cells during cancer development. And finally, the lab develops proof of concepts for macrophage-targeted therapies to enhance T-cell immunity against tumors and to improve response to checkpoint blockade immunotherapies.

Lisa Hoffmann-Haas

Nature Cancer
Berlin, Germany

Lisa Hoffmann-Haas obtained her master's degree from the University of Vienna, during which she was trained in the laboratory of Jacqui Shields at the MRC Cancer Unit in Cambridge, UK. She then completed her PhD in the laboratory of Anna Obenauf at the Institute of Molecular Pathology (IMP) in Vienna, Austria. Her doctoral research was based on the intersection of targeted therapy and immunotherapy and focused on understanding the effects of acquired resistance to targeted therapy on the tumor microenvironment. She joined Nature Cancer in 2021 as the handling editor for tumor immunology and immunotherapy, metastasis and metabolism and is based in the Berlin office.

Eynav Klechevsky

Washington University School od Medicine
St. Louis, United States of America

Eynav Klechevsky's research has focused on understanding antigen presentation by tumors and dendritic cells, and on unraveling the functional specializations of distinct human dendritic cell subsets in tissue. Her laboratory at the Washington University School of Medicine has since been devoted to elucidating the molecular regulators that control dendritic cell ability to drive adaptive processes and maintain immune homeostasis. Of particular significance to cancer immunotherapy, her group made pioneering contributions to elucidating mechanisms that enhance checkpoint immunotherapy responses. Additionally, her laboratory is now actively involved in harnessing such mechanisms to develop cancer vaccines and innovative immune checkpoint intervention strategies.

Robert Manguso

Massachusetts General Hospital Cancer Center
Charlestown, United States of America

Rob Manguso is an Assistant Professor of Medicine in the Massachusetts General Hospital Cancer Center and Harvard Medical School and an Associate Member in the Cancer Program at the Broad Institute of MIT and Harvard. He has made major contributions in target discovery for cancer immunotherapy using in vivo CRISPR-based genetic screens. His lab focuses on understanding the basic mechanisms of immune evasion by tumors, developing therapeutic strategies to overcome immunotherapy resistance, and creating new technologies and methods to probe the interactions between tumor cells and host cells in vivo.

Marcela Maus

Massachusetts General Hospital Cancer Center
Charlestown, United States of America

Marcela Maus is an Associate Professor at Harvard Medical School, the Paula O'Keefe Chair in Oncology and Director of Cellular Immunotherapy at Massachusetts General Hospital Cancer Center, and an Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology. She is an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute. She is internationally known for her work as a translational physician-scientist in the field of immunology, particularly as it relates to T-cell immunotherapies and cellular therapies in the treatment of cancer. Her laboratory focuses on the biology of human T-cell activation, costimulation, and memory, and on the application of human T-cell therapies to human disease, including forward and reverse translation of engineered T-cell therapies in early-phase clinical trials.

Lisa McShane

National Institutes of Health / National Cancer Institute
Bethesda, United States of America

Lisa Meier McShane is Associate Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, U.S. National Institutes of Health, where she heads the Biometric Research Program, comprising Biostatistics and Computational and Systems Biology Branches. She is an expert on precision medicine clinical trial design; development of tumor markers and omics predictors for prognosis, therapy selection, and disease monitoring; and reporting guidelines for health research studies. She served on American Society of Clinical Oncology committees that developed guidelines for HER2, hormone receptor and other biomarker testing in breast cancer, and EGFR mutation testing in lung cancer.

Ira Mellman

Genentech
San Francisco, United States of America

Ira Mellman came to Genentech after more than 20 years as a faculty member at the Yale University School of Medicine, a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Ira Mellman's laboratory is known for advances in fundamental cell biology in the area of membrane traffic and the discovery of endosomes, and for applying these insights to understanding the cellular basis of the immune response. Of particular importance have been his pioneering research on how dendritic cells initiate immunity or maintain immune tolerance. Recently, his group has turned to elucidating how T-cell signaling is regulated by immune checkpoints, and how personalized cancer vaccines and cell-based therapies can be used to enhance anti-tumor T-cell responses.

Miriam Merad

Icahn School of Medicine at Mount Sinai
New York, United States of America

Miriam Merad is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC). Miriam Merad identified the tissue resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on the development of novel macrophage-targeted therapies for these conditions. She identified a new subset of dendritic cells, which is now considered a key target of antiviral and antitumor immunity. In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.

BIONTECH

Ushering in a new era of high-precision medicines

At BioNTech, scientists are pioneering the discovery and development of novel therapies for cancer and other serious diseases. We combine a variety of advanced therapeutic platforms and bioinformatics tools to develop individualized treatments and potent immunotherapies. Our vision is to improve the health of people worldwide by harnessing the full potential of the immune system.

Transforming patients' lives through science™

We are in the business of breakthroughs—our diverse, promising pipeline is focused on innovative medicines that transform patients' lives. Our scientists are addressing some of the most challenging diseases of our time, cancer among them. We will never give up our search for more hope, for more patients, around the world.

Bristol Myers Squibb™

bms.com/de

NO-DE-2300015

Miriam Meyer

Immatics
Munich, Germany

Miriam Meyer is Head of Regulatory Affairs at Immatics and oversees strategic and operational RA for Immatics' cellular and bispecific product pipeline as well as for companion diagnostics. She brings 20 years of experience in Regulatory Affairs for oncology and generic drugs. Miriam holds a PhD from her work at the Max-Planck-Institute for Biochemistry in Munich and a Master of Drug Regulatory Affairs.

Ali Salanti

University of Copenhagen
Copenhagen, Denmark

Ali Salanti leads a team of 35 research scientists at University of Copenhagen. Early in his career, he focused his research on exploring the molecular mechanisms behind parasite sequestration in the human placenta with the perspective of aiding malaria sick women with a prophylactic vaccine. He identified the VAR2CSA malaria protein as the key parasite protein binding to chondroitin sulfate in the placenta. He and colleagues have taken this discovery to several clinical trials in Africa. Further, Salanti and team invented a novel vaccine delivery platform using capside virus like particles, and have among other targets used this platform for development of a SARS-COV-2 vaccine now in phase 3 clinical trial and an HER2 vaccine that will enter clinical trial within a year.

Koustubh Ranade

Immunocore
Rockville, United States of America

Koustubh Ranade is Head of Translational Medicine at Immunocore with responsibility for biomarkers, companion diagnostics, clinical pharmacology, genomics and data science. Prior to this role, he was Vice President of Translational Medicine at MedImmune/AstraZeneca for all therapeutic areas, where he and his team contributed to seven product approvals across multiple therapeutic areas for diseases including respiratory, autoimmune and cancer. With over three decades of research experience at Genentech, BMS, Stanford and NIH, Koustubh is a co-inventor on many patents, has published extensively in top-tier journals and has edited a book on the application of genomics to drug development.

Seth Thomas Scanlon

Science
Ede, The Netherlands

Seth Scanlon is a Senior Editor at Science. His areas of responsibility include immunology, hematology, and host–pathogen interactions. His undergraduate work on lung surfactant proteins was with Michael Beers at the University of Pennsylvania. This was followed by a doctorate at the University of Chicago under the supervision of Albert Bendelac on the role of semi-invariant NKT-cells in asthma. He then studied type 2 innate lymphoid cell (ILC2) regulation and trafficking in Andrew McKenzie's group at the MRC Laboratory of Molecular Biology in Cambridge, UK. Seth has been with Science since June 2017 and currently works for AAAS International office (Cambridge, UK).

Anne Rios

Princess Máxima Center for Pediatric Oncology
Utrecht, The Netherlands

Anne Rios started her scientific career by developing and applying advanced imaging technologies to gain insight into developmental processes and stem cell biology. The 3D imaging technology she developed allows for visualization of intact organs, tumors, and organoids up to sub-cellular resolution and can reveal novel and unexpected features of both normal organ development and function, as well as cancer progression. As a group leader and head of the imaging center of the Princess Máxima Center for Pediatric Oncology, she combines organoid, multi-spectral 3D imaging expertise and AI-based analytical framework to drive discovery into the underlying mechanisms of cancer and advance immunotherapies for solid tumor targeting.

Christoph Scheiermann

University of Geneva/Ludwig-Maximilians-Universität
Geneva, Switzerland/Munich, Germany

Christoph Scheiermann studied biochemistry at Freie Universität (FU) Berlin, Germany, and MIT, Boston, USA. He received his Ph.D. in vascular biology with Sussan Nourshargh from Imperial College London, UK, before joining the laboratory of the late Paul S. Frenette at Mount Sinai School of Medicine and later Albert Einstein College of Medicine in New York City, USA. He is the recipient of a Starting and Consolidator grant from the European Research Council (ERC). He is currently associate professor at the University of Geneva, Switzerland, and has a second affiliation with Ludwig-Maximilians-Universität (LMU) in Munich, Germany. His lab focuses on the circadian regulation of immune functions and neuroimmune interactions.

Samra Turajlic

The Francis Crick Institute; Royal Marsden Hospital
London, UK

Samra Turajlic has contributed the first insights into the genome landscape of non-UV associated melanomas, and genetic mechanisms of resistance to targeted therapies in melanoma. In 2014, she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute. Her post-doctoral work contributed the first evolutionary classification of renal cancer, and key evolutionary determinants of the disease course. In 2015, she was appointed a Consultant Medical Oncologist on the Skin and Urology Units at the Royal Marsden NHS Foundation Trust focusing on the treatment of melanoma and renal cancer. She divides her time between the clinic and her lab, Cancer Dynamics.

Sjoerd van der Burg

Leiden University Medical Center
Leiden, The Netherlands

Sjoerd H. van der Burg has been professor in experimental cancer immunology and therapy at the department of medical oncology at Leiden University Medical Center since 2010 and Senior Investigator of the Oncode Institute since 2019. He leads the experimental cancer immunology and therapy group which performs fundamental, translational, and clinical studies focusing on those factors of host-tumor interactions that determine the success and failure in immune control of cancer. His group has published several seminal studies on immunotherapy of cancer, in particular in the context of therapeutic vaccines, and (co-)initiated a series of investigator-initiated clinical trials.

Hilke Zander

Paul-Ehrlich-Institut
Langen, Germany

Hilke Zander is clinical assessor at the Paul-Ehrlich-Institut (PEI) in the section of monoclonal and polyclonal antibodies. At PEI, she has been working on oncological antibody therapies and in particular on the marketing authorisation of checkpoint-inhibitors. With her involvement in the evaluation of targeted therapies, her focus has shifted to the co-development of companion diagnostics and medicinal products and the implementation of the In Vitro Diagnostica Regulation 746/201. In addition to the implementation of a new official task, the evaluation of IVD performance studies, at the PEI, she is member in various European committees, e.g. the IVD-CDx subgroup of the CTFG, the CDx Expert Group on the implementation of theCDx "consultation procedure" and the scientific advice working party (SAWP) of the EMA.

INDUSTRY TALKS

LUNCH AND LEARN

Andreas Weigert
Universitätsklinikum Frankfurt
Frankfurt, Germany

BD

Yu-Chih Lin
Sino Biological
Frankfurt, Germany

Sino Biological

vizgen

20 YEARS OF ANNUAL MEETINGS

Since 2003, the CIMT Annual Meeting has connected the cancer immunotherapy community in the heart of Europe, facilitating the knowledge exchange between academic and industry scientists, physicians, and regulatory authorities who research and develop cancer immunotherapies.

From focused plenary sessions to lively poster and industry exhibits and rocking CIMT Social Events: at the CIMT Annual Meetings, new ideas are introduced, collaborations are forged, and friendships develop. Countless early-career investigators have been given the opportunity to present their research in front of a large audience and have received invaluable feedback from international experts and pioneers of the field.

The CIMT Annual Meeting could not be held only once: The 18th CIMT Annual Meeting had to be canceled due to the COVID-19 pandemic. It was held in a virtual format in the following year.


CIMT
CIMT
CIMT


mes P. Allison

ANNUAL MEETING

CIMT LIFETIME ACHIEVEMENT AWARD 2023

Hans-Georg Rammensee

The CIMT Lifetime Achievement Award honors a European researcher who has significantly contributed to the advancement of cancer immunotherapy. The award was inaugurated in 2017 and is bestowed every other year.

The German immunologist Hans-Georg Rammensee is the recipient of the 2023 CIMT Lifetime Achievement Award for his extraordinary achievements in cancer immunology, in particular the understanding of peptide-antigen presentation on MHC molecules and his seminal work on personalized cancer vaccination. Hans-Georg Rammensee is the director of the Department of Immunology at the University of Tübingen.

Prof. Rammensee's lifetime achievements are a milestone in the history of immunology, particularly his research on the identification and description of the rules that guide the interaction of peptides with MHC molecules. His work has contributed significantly to the understanding of the specificity of T-cell recognition and the establishment of T-cell tolerance, as well as the design and function of vaccines. This allowed the first exact predictions of naturally presented peptides from self and foreign antigens and laid the foundation for the development of bioinformatic analysis tools for the identification of antigens recognized by T-cells in infection, cancer, and autoimmunity, leading to the development of new technologies for T-cell analysis, and the building of databases for MHC presented peptides in health and disease.

Prof. Rammensee pioneered the application of mass spectometry and bioinformatics methods in immunology which have been used to precisely predict and determine cancer-associated peptides presented on MHC molecules, including neoantigens. With colleagues Prof. Dr. Günther Jung and Prof. Dr. Karl-Heinz Wiesmüller, his team was able to show that peptide-specific T-cells can be induced against the influenza virus using a component of the bacterial cell membrane as a vaccine booster.

A major research focus of Prof. Rammensee has been on personalized cancer vaccination, applying and translating the knowledge obtained from experimental models for the design of personalized vaccination in clinical studies.

Moreover, he is one of the pioneers of mRNA vaccination. He already made extraordinary achievements in this field more than 25 years ago: With colleague Prof. Dr. Günther Jung and their PhD student Ingmar Hoerr, the team was able to show that T-cells and antibodies can be induced against a model antigen, laying the scientific basis for a method to produce mRNA vaccines. Using his approach towards therapeutic cancer vaccines, Prof. Rammensee's goal is to be able to immunize with cancer-specific peptides recognized by T-cells to develop innovative therapeutic approaches and individualized production of modern drugs for immunotherapies.

From his academic research, several companies have spun out under his guidance, among these are CureVac, Immatics Biotechnologies, and Synimmune.

From 1974 to 1980, Rammensee studied biology at the Eberhard Karl University in Tübingen where he received his PhD under Jan Klein at the Max-Planck-Institute for Biology. After a post-doctoral fellowship at the Scripps Institute in La Jolla and then member of the Basel Institute for Immunology, he moved back to Tübingen where he headed a research group on Immunology at the Max Planck Institute from 1987 to 1993. From 1993 to 1996, he became professor at the University of Heidelberg and headed the Tumor Virus Immunology Division at the German Cancer Research Center in Heidelberg. He then returned to the University of Tübingen where he directs the Department of Immunology in the Interfaculty Institute of Cell Biology. In 2022, he became a member of the German National Academy of Sciences Leopoldina.

FLOOR PLAN

OVERVIEW

RHEINGOLDHALLE CONGRESS CENTER



PROGRAM

SESSION OVERVIEW

	DAY 1 - MAY 3	DAY 2 - MAY 4	DAY 3 - MAY 5
08:00-08:30	Registration		
08:30-09:00		**Session 3** Novel Targets Sebastian Amigorena Ali Salanti Vinod Balachandran	**Session 5** Immune Escape Adelheid Cerwenka Robert Manguso Ira Mellmann
09:00-09:30			
09:30-09:45	**Welcome Address**		
09:45-10:00			
10:00-10:30	**Session 1** Improving Immunity Samra Turajlic Guoliang Cui Niels Halama	Coffee Break	Coffee Break
10:30-11:00		**Short Talk Session I**	**Short Talk Session III**
11:00-11:30			
11:30-12:00	Lunch	**Short Talk Session II**	**Short Talk Session IV**
12:00-12:30	**Industry Talks** Company Talks		
12:30-13:00		Lunch CIMT Members Meeting **Meet the Editors** Lisa Hoffmann-Haas Priscilla Kelly Feline Dijkgraaf John Haanen	**Short Talk Session V**
13:00-13:15			**Short Talk Session VI**
13:15-13:30			Lunch
13:30-14:00	**Session 2** Tumor Microenvironment Anne Rios Miriam Merad Sjoerd van der Burg		**Regulatory Research** Koustubh Ranade Miriam Meyer Stefan Fröhling Hilke Zander
14:00-14:30		**Session 4** Orchestrating Immunity Christoph Scheiermann Julie Helft Eynav Klechevsky	
14:30-14:45			
14:45-15:00			**Poster Awards**
15:00-15:30	**Poster Session I** + **Coffee Break**		**Session 6** Cellular Therapies George Coukos John Haanen Marcela Maus
15:30-16:00			
16:00-16:30		**Poster Session II** + **Coffee Break**	
16:30-17:00			Conference Closing
17:00-17:30			
17:30-18:00	**Keynote Lecture** Rafi Ahmed		
18:00-18:30		**Lifetime Achievement Award**	
18:30-19:00			
19:00-19:30			
19:30-24:00		**Social Event**	

* Sessions and times are subject to change

ScaleReady

Translate with speed.
Manufacture with consistency.
Scale without limitation.

Future-proof your cell and gene therapy process.

scaleready.com



ANNUAL MEETING

PROGRAM SCHEDULE

Day 1 – May 3

08:30 - 09:45	Congress Hall	REGISTRATION AND WELCOME COFFEE Sign-in and badge pickup
09:45 - 10:00	Congress Hall	WELCOME Christoph Huber, CIMT, Mainz, Germany Clemens Hoch, Minister for Science and Health of Rhineland-Palatinate, Germany
10:00 - 11:30	Congress Hall	PLENARY SESSION 1 IMPROVING IMMUNITY Supported by: Helmholtz-Institut für Translationale Onkologie HI-TRON Mainz Chairs: Stefan Tenzer (University Medicine Mainz, Mainz, Germany), Angelika Riemer (German Cancer Research Center DKFZ, Heidelberg, Germany)
10:00 - 10:30		Samra Turajlic (The Francis Crick Institute/Royal Marsden Hospital, London, United Kingdom) "Routes to immune invasion in renal cancer and melanoma"
10:30 - 11:00		Guoliang Cui (HI-TRON/German Cancer Research Center DKFZ, Mainz/Heidelberg, Germany) "Regulatory T-cell metabolism in the tumor microenvironment"
11:00 - 11:30		Niels Halama (German Cancer Research Center DKFZ, Heidelberg, Germany) "Immuno-metabolic modulation in pancreatic cancer: glycemic control, immune responses and chemotherapy"
11:30 - 13:30	Rhine Foyer	LUNCH
12:00 - 13:00	Congress Hall	LUNCH & LEARN INDUSTRY TALKS
12:00 - 12:20		Andreas Weigert (Universitätsklinkum Frankfurt, Frankfurt, Germany) "High-parameter analyses" Presented by: BD
12:20 - 12:40		Yu-Chih Lin (Sino Biological, Frankfurt, Germany) "Accelerating drug discovery using advanced protein and antibody development platforms" Presented by: SinoBiological
12:40 - 13:00		Dries van Hemelen (Vizgen, Vienna, Austria) "Constructing a spatially resolved cancer cell atlas with the MERSCOPE platform" Presented by: vizgen

Day 1 – May 3

13:30 - 15:00	Congress Hall	PLENARY SESSION 2 TUMOR MICROENVIRONMENT Chairs: Michael Platten (University Medicine Mannheim, Mannheim, Germany), Viktor Umansky (German Cancer Research Center DKFZ, Heidelberg, Germany)
13:30 - 14:00		Anne Rios (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands), "Organoid cellular cancer immunity models in motion"
14:00 - 14:30		Miriam Merad (Icahn School of Medicine at Mount Sinai, New York, United States of America) "Targeting dendritic cells in cancer"
14:30 - 15:00		Sjoerd van der Burg (Leiden University Medical Center, Leiden, The Netherlands) "Single-cell spatial in situ transcriptomics unravels vulvar HSIL composition associated with complete response to immunotherapy"
15:00 - 17:30	Rhine Foyer	COFFEE BREAK
15:00 - 17:30	East and West Foyers	POSTER SESSION I Improving Immunity, Immunomonitoring, Cellular Therapy
17:30 - 18:30	Congress Hall	KEYNOTE LECTURE Chair: Christoph Huber (CIMT, Mainz, Germany) Rafi Ahmed (Emory University School of Medicine, Atlanta, United States of America) "T-cell lifestyle during chronic infection and cancer: implications for immunotherapy"

Day 2 – May 4

08:30 - 10:00	Congress Hall	PLENARY SESSION 3 NOVEL TARGETS Chairs: Hansjörg Schild (University Medicine Mainz, Mainz, Germany), Carl Figdor (Radboud University Medical Center, Nijmegen, The Netherlands)
08:30 -09:00		Sebastian Amigorena (Institut Curie, Paris, France) "Epigenetics tumor antigens"
09:00 - 09:30		Ali Salanti (University of Copenhagen, Copenhagen, Denmark) "Targeting onco-fetal glycosaminoglycans omnipresent in the tumor microenvironment"
09:30 - 10:00		Vinod Balachandran (Memorial Sloan Kettering Cancer Center, Charlestown, United States of America) "Pancreatic cancer – clinical discovery to new immunotherapies"

Day 2 – May 4

10:00 - 10:30	Rhine Foyer	COFFEE BREAK
10:30 - 12:00	Gutenberg Hall A	SHORT TALK SESSION I CELLULAR THERAPY Chairs: Andrew Kaiser (BioNTech, Mainz, Germany), Hideho Okada (University of California, San Francisco, United States of America)
10:30 - 10:45		Viktoria Blumenberg (University Hospital LMU Munich, Munich, Germany) "Gut microbial taxa are linked to beneficial or adverse CAR T-cell immunophenotypes and outcomes in lymphoma patients treated with CD19-targeted CAR T-cells"
10:45 - 11:00		Dora Hammerl (Pan Cancer T, Rotterdam, The Netherlands) "T-cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer"
11:00 - 11:15		Barbara Lösch (Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany) "Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment"
11:15 - 11:30		Alexandre Marraffa (Erasmus MC, Rotterdam, The Netherlands) "T-cell receptors equipped with ICOS demonstrate enhanced control of melanoma recurrence and T-cell longevity upon adoptive therapy in vivo"
11:30 - 11:45		Jennifer Modamio Chamarro (Helmholtz Zentrum, Munich, Germany) "Analysis of the bio-distribution and targeting efficacy of CAR T-cell therapy in a whole mouse body"
11:45 - 12:00		Kristen Vogt (Weill Cornell Medicine, New York City, United States of America) "Tumor microenvironment actuated GD2 CAR T-cells prevent on-target off-tumor toxicities"
10:30 - 12:00	Gutenberg Hall B	SHORT TALK SESSION II IMPROVING IMMUNITY Chairs: Markus Maeurer (Champalimaud Foundation, Lisbon, Portugal), Michal Bassani-Sternberg (University Hospital Lausanne, Lausanne, Switzerland)
10:30 - 10:45		Honglu Ding (Sun Yat-sen University Cancer Center, Sun Yat-Sen University, Guangzhou, China) "A STING signaling relay from tumor cells to macrophage cells contributed to combinational chemotherapy efficacy on pancreatic ductal adenocarcinoma"
10:45 - 11:00		Yumeng Mao (Uppsala University, Uppsala, Sweden) "Interleukin-1 receptor-associated kinase 3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy"
11:00 - 11:15		Christopher Medina (Emory University, Atlanta, United States of America) "Phosphatidylserine exposure on exhausted CD8 T-cells operates as a non-classical inhibitory molecule"

Day 2 – May 4

11:15 - 11:30		Naveen K. Mehta (Cullinan Oncology, Cambridge, United States of America) "CLN-617 is a first-in-class fusion protein that retains IL-2 and IL-12 in injected tumors and potently triggers systemic anti-tumor immunity"
11:30 - 11:45		Hannah Newnes (The University of Western Australia, Nedlands, Australia) "Manipulating the balance of pro- and anti-inflammatory signals in the tumour microenvironment to enhance cancer control"
11:45 - 12:00		Marjolein Schluck (Radboud University Medical Center, Nijmegen, The Netherlands) "Density and ratio of stimulatory antibodies on immunofilaments influence ex vivo T-cell expansion and phenotype"
12:00 - 14:00	Rhine Foyer	LUNCH
12:30 - 13:30	Congress Hall	MEET THE EDITORS Chair: Jan Beck (BioNTech, Mainz, Germany) Seth Scanlon (Science) Feline Dijkgraaf (Cancer Cell) Lisa Hoffmann-Haas (Nature Cancer) John Haanen (IOTECH)
12:30 - 13:30	Zagreb Room	CIMT MEMBERS MEETING
14:00 - 15:30	Congress Hall	PLENARY SESSION 4 ORCHESTRATING IMMUNITY Chairs: Kees Melief (ISA Pharmaceuticals, Leiden, The Netherlands), Thomas Kindler (University Medicine Mainz, Mainz, Germany)
14:00 - 14:30		Christoph Scheiermann (Ludwig Maximilians University, Munich, Germany) "The circadian immune system in cancer"
14:30 - 15:00		Julie Helft (Institut Cochin–INSERM, Paris, France) "Macrophage subsets and T-cell immunity in breast cancer"
15:00 - 15:30		Eynav Klechevsky (Washington University School of Medicine, St. Louis, United States of America) "Regulation and dysregulation of tumor immunity by human dendritic cell subsets"
15:30 - 18:00	Rhine Foyer	COFFEE BREAK
15:30 - 18:00	North and Lower Rhine Foyers	POSTER SESSION II Therapeutic Vaccination, New Targets & New Leads, Tumor Biology & Interaction with the Immune System

Day 2 – May 4

18:00 - 18:30	Congress Hall	LIFETIME ACHIEVEMENT AWARD Honoring Hans-Georg Rammensee
19:30 - 23:00	Altes Postlager	SOCIAL EVENT "Altes Postlager". Entry tickets required. Food and drinks for purchase at venue.

Day 3 – May 5

08:30 - 10:00	Congress Hall	PLENARY SESSION 5 IMMUNE ESCAPE Chairs: Stephan Grabbe (University Medicine Mainz, Mainz, Germany), Renata Stripecke (University Hospital Cologne, Cologne, Germany)
08:30 - 09:00		Adelheid Cerwenka (University of Heidelberg Medical Faculty Mannheim, Mannheim, Germany) "Natural killer cells in solid cancer"
09:00 - 09:30		Robert Manguso (Massachusetts General Hospital Cancer Center, Charlestown, United States of America) "In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer"
09:30 - 10:00		Ira Mellman (Genentech, San Francisco, United States of America) "Mechanistic basis of cancer immunotherapy"
10:00 - 10:30	Rhine Foyer	COFFEE BREAK
10:30 - 12:00	Gutenberg Hall A	SHORT TALK SESSION III NEW TARGETS & NEW LEADS Chairs: Catherine Wölfel (University Medicine Mainz, Mainz, Germany), Rienk Offringa (German Cancer Research Center DKFZ, Heidelberg, Germany)
10:30 - 10:45		Seth Anderson (Broad Institute of MIT and Harvard, Cambridge, United States of America) "Genome-scale in vivo CRISPR screens identify Erap1 as a non-classical MHC-I-dependent immunotherapy target"
10:45 - 11:00		Michela Capello (Genmab B.V., Utrecht, The Netherlands) "GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity"
11:00 - 11:15		Dennis Kirchhoff (DKFZ-Bayer Joint Immunotherapeutics Laboratory, Heidelberg, Germany) "BAY 2965501: A highly selective DGK- ζ-inhibitor for cancer immuno-therapy with first-in-class potential "

Day 3 – May 5

11:15 - 11:30		Eran Ophir (Compugen, Holon, Israel) "Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity"
11:30 - 11:45		Remko Schotte (Kling Biotherapeutics, Amsterdam, The Netherlands) "Identification and development of KBA1412, a fully human, first-in-class CD9 antibody for the treatment of cancer"
11:45 - 12:00		Adriana Turqueti Neves (iOmx Therapeutics, Munich/Martinsried, Germany) "Novel myeloid immune checkpoints identified by iOTarg, a function-based high-throughput discovery platform"
10:30 - 12:00	Gutenberg Hall B	SHORT TALK SESSION IV TUMOR BIOLOGY & INTERACTION WITH THE IMMUNE SYSTEM Chairs: Kalijn Bol (Radboud University Medical Center, Nijmegen, The Netherlands), Toszka Bohn (University Medicine Mainz, Mainz, Germany)
10:30 - 10:45		Mihaela Angelova (The Francis Crick Institute, London, United Kingdom) "Spatial Architecture of Myeloid and T-cells Orchestrates Immune Evasion and Clinical Outcome in TRACERx"
10:45 - 11:00		Federica Benvenuti (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy) "Type 1 DCs drive anti-tumoral immunity to endogenous immunogenic neoantigens in lung cancer"
11:00 - 11:15		Judit Díaz-Gómez (Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) "Unravelling tumor-intrinsic resistance mechanisms to T-cell mediated cytotoxicity in pancreatic cancers"
11:15 - 11:30		Hideho Okada (University of California, San Francisco, United States of America) "Glioma-induced neuronal remodeling promotes regional immunosuppression"
11:30 - 11:45		Tamara Verkerk (Sanquin Research, Amsterdam, The Netherlands) "Expression of neolacto-series glycosphingolipids by tumors impairs the anti-tumor function of innate and adaptive immune responses."
11:45 - 12:00		Stefan Zens (German Cancer Research Center DKFZ, Heidelberg, Germany) "Charting the tumor-reactive T-cell repertoire in DNA damage repair (DDR) deficient pancreatic cancer towards development of personalized T-cell therapy"
12:00 - 13:00	Gutenberg Hall A	SHORT TALK SESSION V IMMUNOMONITORING Chairs: Cécile Gouttefangeas (University of Tübingen, Tübingen, Germany), Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)
12:00 - 12:15		Marieke Fransen (Amsterdam UMC, Amsterdam, The Netherlands) "Correlation of peripheral blood immune markers with complete pathological response in a clinical trial of neoadjuvant chemoradiotherapy combined with dual immunotherapy followed by resection in locally advanced NSCLC patients"

Day 3 – May 5

12:15 - 12:30		Bastian Höchst (Institute of Molecular Immunology and Experimental Oncology, Munich, Germany) "Detection of HER2-positive extracellular vesicles in plasma from breast cancer patients using spectral flow-cytometry"
12:30 - 12:45		Hester van Zeeburg (Mendus AB, Stockholm, Sweden) "High dimensional analysis of peripheral blood mononuclear cells in AML patients shows a beneficial tumor reactive T-cell environment at start of treatment in patients responding to an allogenic leukemia-derived cancer vaccine (vididencel)"
12:45 - 13:00		Kilian Wistuba-Hamprecht (Section for Clinical Bioinformatics, Department of Internal Medicine I, Tübingen, Germany) "High-dimensional in situ proteomics imaging to assess γδT-cells in human tissues"
12:00 - 13:00	Gutenberg Hall B	SHORT TALK SESSION VI THERAPEUTIC VACCINATION Chairs: Steve Pascolo (University Hospital of Zurich, Zurich, Switzerland), Mathias Vormehr (BioNTech, Mainz, Germany)

Day 3 – May 5

12:00 - 12:15		Lei Cui (Sun Yat-sen University Cancer Center, Sun Yat-Sen University, Guangzhou, China) "A STING agonist potentiates a C1 lipid-based mRNA cancer vaccine through promoting TNFα secretion in dendritic cells."
12:15 - 12:30		Niklas Grassl (German Cancer Research Center DKFZ, Heidelberg, Germany) "A long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with diffuse midline glioma"
12:30 - 12:45		Erika Riva (AMAL Therapeutics, Geneva, Switzerland) "NKG2A blockade oppositely impacts intra-tumoral and peripheral CD8 T-cell response induced by KISIMA – VSV-GP heterologous vaccination"
12:45 - 13:00		Marij Welters (Leiden University Medical Center, Leiden, The Netherlands) "Phase I/II clinical trial targeting alternative shared neoantigens (TEIPP) in checkpoint-resistant non-small cell lung cancer."
13:00 - 15:00	Rhine Foyer	LUNCH
13:15 - 14:45	Congress Hall	REGULATORY RESEARCH Chairs: Cedrik Britten (Immatics, Tübingen, Germany), Stefan Fröhling (German Cancer Research Center DKFZ and NCT Heidelberg, Heidelberg, Germany)
13:15 - 13:25		Introduction
13:25 - 13:40		Koustubh Ranade (Immunocore, Rockville, United States of America) "Tebentafusp-a gp100 directed TCR-CD3 bispecific for the treatment of metastatic uveal melanoma"
13:40 - 13:55		Hilke Zander (Paul-Ehrlich-Institut, Langen, Germany) "Evolving regulatory framework for IVDs and CDxs (IVDR)"
13:55 - 14:15		Miriam Meyer (Immatics, Tübingen, Germany) "HLA genotyping for T-cell therapy"
14:15 - 14:30		Lisa McShane (National Institutes of Health, National Cancer Institute, United States of America) "Genomic screening for actionable genomic alterations - experience from NCI precision medicine platform trials"
14:30 - 14:45		Stefan Fröhling (German Cancer Research Center DKFZ and NCT Heidelberg, Heidelberg, Germany) "RNA sequencing to facilitate patient enrollment into biomarker-guided clinical trials"
14:45 - 15:00	Congress Hall	POSTER AWARDS

Day 3 – May 5

15:00 - 16:30	Congress Hall	PLENARY SESSION 6 CELLULAR THERAPY Chairs: Matthias Theobald (University Medicine Mainz, Mainz, Germany), Johanna Olweus (Oslo University Hospital, Oslo, Norway)
15:00 - 15:30		George Coukos (CHUV/UNIL-Ludwig Institute for Cancer Research, Lausanne, Switzerland) "Learning from natural immunity to create synthetic immunity"
15:30 - 16:00		John Haanen (The Netherlands Cancer Institute, Amsterdam, The Netherlands) "Cell therapy of solid tumors: TIL and beyond"
16:00 - 16:30		Marcela Maus (Massachusetts General Hospital Cancer Center, Charlestown, United States of America) "Insights into CAR T-cell mechanisms"
16:30 - 16:35	Congress Hall	CONFERENCE CLOSING

FOSUN PHARMA
Innovation for Good Health

Innovation for Good Health

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of "innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

Core Therapeutic Areas



Key innovative products on the markets

COMIRNATY®
(mRNA COVID-19 vaccine, also known as BNT162b2)
The world's first mRNA COVID-19 vaccine fully approved by FDA

Han Li Kang
(Rituximab injection)
The first biosimilar product approved in China

Han Qu You
(Trastuzumab Injection)
The first mAb product approved in both China and the EU

Han Si Zhuang
(Serplulimab injection)
The first self-developed innovative monoclonal antibody

Yi Kai Da
(Axicabtagene Ciloleucel Injection)
The first CAR-T cell therapy product approved for launch in China

Artesun®
(Artesunate for Injection)
China's No.X-01 New Drug, saved more than 48 million lives of severe malaria patients

Jie Bei An
(Azulfidine Tablets)
The first domestic small molecule anti Covid-19 oral drugs

Su Ke Xin
(Avatrombopag Maleate Tablets)
The first small-molecule innovative drug introduced

Akynzeo
(Netupitant and Palonosetron Hydrochloride Capsules)
The World's first and only oral combination anti-emetic preparation that synergically blocks two key CINV receptor pathways (5-HT3 and NK1)

Otezla
(Apremilast tablets)
The first and only orally-administered phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis in China

ANNUAL MEETING

2023 INDUSTRY EXHIBITORS

ANNUAL MEETING

2023 INDUSTRY EXHIBITORS



1 Boehringer Ingelheim
2 BD Life Science
3 Nanolive SA
4 Sino Biological
5 JPT
6 CTL Europe GmbH
7 Proteintech
8 Lunaphore Technologies
9 MedChemExpress
10 PeproTech GmbH
11 biomindz
12 OMNI Life Science
13 Mabtech
14 OriGene Technologies
15 ImmunAware
16 ScaleReady
17 Promega
18 Miltenyi Biotec
19 Immudex
20 ABclonal
21 INTEGRA
22 Taconic Biosciences
23 Creative BioMart
24 abcam
25 GenScript
26 STEMCELL Technologies
27 Bio-Techne
28 Luminex
29 LGC Standards
30 BioLegend
31 BMS
32 Vizgen

[A]

abcam **24**
273 Hover Ave.
12526, Germantown, NY, United States of America
www.abcam.com
Biological reagents and solutions that enable faster breakthroughs in critical areas like cancer, neurological disorders, infectious diseases and metabolic disorders.

ABclonal **20**
Prinzenallee 7
40549 Düsseldorf, Germany
eu.abclonal.com
Reliable and cost-effective products and services for both basic and translational research, including high-quality biology research reagents, tools, and custom services.

[B]

BD Life Science **2**
Tullastraße 8-12
69126 Heidelberg, Germany
www.bdbiosciences.com/en-de
Innovative technology, services and solutions to advance both clinical therapy for patients and clinical process for health care providers. BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Bio-Techne **27**
19 Barton Lane
OX14 3NB, Abingdon, United Kingdom
www.bio-techne.com
Full-solution provider for ancillary reagents, services and analytical solutions for cell & gene therapy workflows at every step of the research, development, and manufacturing process.

BioLegend GmbH **30**
Anton-Jordan-Str.1
56070 Koblenz, Germany
www.biolegend.com
World-class, cutting-edge antibodies and reagents for a diverse set of applications to drive cancer research—from flow cytometry to immunoassays to multiomics.

biomindz **11**
Schillerplatz 18
55116 Mainz, Germany
www.biomindz.com
Promoting Mainz as a future life science and biotechnology hub with a focus on immunology and individualized medicine.

BMS - Bristol-Myers Squibb GmbH & Co. KGaA . . 31
Arnulfstraße 29
80636 München, Germany
www.bms.com/de
Research and development of drugs for oncology, hematology, immunology, cardiovascular, neurological/neuromuscular diseases and fibrosis.

Boehringer Ingelheim Pharma GmbH & Co. KG 1
Binger Strasse 173
55216 Ingelheim am Rhein, Germany
www.boehringer-ingelheim.de
Research-driven biopharmaceutical company. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 53,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

[C]

Creative BioMart Inc.. 23
45-1 Ramsey Road
11967 Shirley, NY, United States of America
www.creativebiomart.net
Recombinant & native proteins, active enzymes, and other biotech products, custom services, including protein expression, purification, and labeling, as well as protein-protein interaction and enzyme activity assays.

CTL Europe GmbH 6
20521 Chagrin Boulevard, Shaker Heights
44122 Ohio, United States of America
www.immunospot.eu
GLP-compliant high throughput ELISPOT analysis for monitoring T-cell immunity in clinical trials (CRO). ELISPOT analyzers , reagents, required for ELISPOT standardization, including reference PBMCs, up to 4 color ImmunoSpot® ELISPOT T and B Cell Kits and Serum-Free-Media.

[G]

GenScript Biotech (Netherlands) B.V. 25
Treubstraat 1, 1st Floor
Rijswijk, 2288 EG, The Netherlands
www.genscript.com
Comprehensive life sciences research services and products including custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, mRNA production, and custom cell line development, catalog antibodies, catalog kits and eStain and eBlot.

[I]

Immudex 19
Bredevej 2a
2830 Virum, Denmark
www.immudex.com
Dextramer® technology for the detection of antigen-specific immune cells, including rare and low-affinity cells, Clinical-Grade Dextramer® (GMP) products and Dextramer® CMV Kits (IVD) manufactured in ISO 13485:2106-certified facilities.

immunAware ApS 15
Agern Alle 3
2970 Horsholm, Denmark
immunAware.com
MHC class I and class II reagents for immune monitoring; highly active recombinant MHC molecules, including the peptide loadable easYmers®; off the shelf reagents, custom production and services

INTEGRA 21
An der Amtmannsmühle 1
35444 Biebertal, Germany
www.integra-biosciences.com
Solutions for pipetting and media preparation for customers in research, diagnostics and quality control. Product line ranges from single channel mechanical pipettes up to 384 channel electronic benchtop platforms.

[J]

JPT Peptide Technologies **5**
Volmerstraße 5
12489 Berlin, Germany
www.JPT.com
PepMix peptide Pools, PepStar Peptide-Microarrays. Products include: PepMix: Antigen-specific ™ pools for T-cell stimulation, immune monitoring, vaccine-efficacy evaluation and adoptive immunotherapy. PepTrack™: Custom libraries for epitope discovery and mapping, immune monitoring.

[L]

LGC Standards GmbH..... **29**
Queens Road, Teddington
Middlesex, TW11 0LY, United Kingdom
www.lgcstandards.com
Manufacturer and service provider of quality assurance and research tools to support clients' anlytical needs.

Luminex á Diasorin Company..... **28**
Von-Hevesy-Straße 3
63128 Dietzenbach, Germany
www.luminexcorp.com
Molecular Diagnostics (MDx) and Life Science and Clinical Tools portfolios providing cost-effective, flexible solutions for hospitals, reference labs, and researchers, as well as innovative xMAP® and flow cytometry solutions.

Lunaphore Technologies SA..... **8**
Route de Lully 5c
1131 Tolochenaz, Switzerland
www.lunaphore.com
Chip technology to extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity.

[M]

Mabtech **13**
Box 1233
13128 Stockholm, Sweden
www.mabtech.com
Optimized immunoassays and instruments, in particular tools for ELISpot, FluoroSpot, and ELISA, monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications.

MedChemExpress **9**
Bergkällavägen 37C
19279 Sollentuna, Sweden
www.medchemexpress.com/
Wide range of high-quality research chemicals and biochemical including novel life-science reagents, reference compounds, APIs, and natural compounds.

Miltenyi Biotec..... **18**
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach, Germany
www.miltenyibiotec.com
Technical solutions for cellular research, cell therapy, and cell manufacturing: instruments, comprehensive scientific support, consultation, and expert training.

[N]

Nanolive SA **3**
Route de Lully 5b
1131 Tolochenaz, Switzerland
www.nanolive.ch
Breakthrough solutions to derisk and accelerate drug discovery and cell therapy that combine screening, imaging and analysis to study living cells label-free.

[O]

OMNI Life Science GmbH & Co.KG..... **12**
Karl-Ferdinand-Braun-Straße 2
28359 Bremen, Germany
www.ols-bio.de
Instruments for cell counting, cell culture, imaging, flow cytometry, and real rime cell analysis as well as media, reagents, consumables, services and consultation: Flow Cytometry, xCELLigence RTCA, CERO 3D.

OriGene Technologies..... **14**
Schillerstraße 5
32059 Herford, Germany
www.origene.com
cDNA clones and vectors, lentiviral as well as AAV particles to CRISPR, siRNA and shRNA and from antibodies, proteins and ELISA kits to lysates, cyto-sections and tissue products.

[P]

PeproTech GmbH..... **10**
Winterhuder Marktplatz 6-7a
22299 Hamburg, Germany
www.thermofisher.com/peprotech
Cytokines and antibodies; GMP cytokines for cell, gene and tissue therapy, animal-free cytokines, ELISA development kits, cell culture media kits / supplements.

Promega GmbH **17**
Gutenbergring 10
69190 Walldorf, Germany
www.promega.com
Gene, protein, and cell analysis solutions for academic and industrial research, extensive toolbox of reporter assays to study Fc effector activity, immune checkpoint modulation, T-cell activation, cytokines, etc.

Proteintech Germany **7**
Am Klopferspitz 19
82152 Planegg, Germany
www.ptglab.com
Antibodies, immunoassays, proteins and nanobodies, comprehensive library of original validation data, product-specific protocols, and over 180,000 product citations

[S]

ScaleReady **16**
2100 Old Highway 8 NW
St. Paul, MN 55112, United States of America
www.scaleready.com
Cell culture, cell activation, gene editing, and cell processing. Platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies

Sino Biological **4**
Düsseldorfer Str. 40
65760 Eschborn, Germany
www.sinobiological.com
Recombinant protein bank (6500+), antigens including viral proteins, cytokines, growth factors, immune checkpoints, antigens for therapeutic targets, Fc receptors and biomarker proteins, CRO services

STEMCELL Technologies **26**
Stolbergerstrasse 200
50933 Köln, Germany
www.stemcell.com
High-quality cell culture media, cell separation technologies, instruments, accessory products, and scientific services that are used by scientists globally.

[T]

Taconic Biosciences **22**
273 Hover Ave.
12526 Germantown, NY, United States of America
www.taconic.com
Specialist in genetically engineered rodent mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services

[V]

Vizgen **32**
61 Moulton Street
Cambridge, MA 02138, United States of America
www.vizgen.com
Providing tools that demonstrate the possibilities of in-situ single-cell spatial genomics. The company's MERSCOPETM Platform enables massively multiplexed, genome-scale nucleic acid imaging with high detection efficiency at subcellular resolution.

SCIENCE IN TRANSLATION

We put inspiration into practice,
finding innovative solutions for complex challenges.

OUR RESEARCH FOCUS:

- *Oncology*
- *Infectious diseases*
- *Autoimmune diseases*
- *Ageing immune system*
- *Cardiovascular diseases*
- *Diseases of the nervous system*

OUR TECHNOLOGIES:

- *Next Generation Sequencing*
- *Live Cell Imaging*
- *Bioinformatics, software development*
- *Immunomonitoring*
- *Biosampling and histology screening*
- *Preclinical models*

TRON gGmbH
Freiligrathstraße 12
55131 Mainz

TRON

POSTER AWARD

POSTER PRESENTATIONS

Abstracts have been selected for poster presentation in six categories.

Immunomonitoring

Poster Session I, May 3, 15:00 - 17:30, East Foyer

Cellular Therapy

Poster Session I, May 3, 15:00 - 17:30, West Foyer

Improving Immunity

Poster Session I, May 3, 15:00 - 17:30, East Foyer

Therapeutic Vaccination

Poster Session II, May 4, 15:30 - 18:00, North Foyer

New Targets & New Leads

Poster Session II, May 4, 15:30 - 18:00, North Foyer

Tumor Biology & Interaction with the Immune System

Poster Session II, May 4, 15:30 - 18:00, Lower Rhine Foyer

supported by immatics

2023 CIMT POSTER AWARD

immatics®

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.

This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Follow us on

www.immatics.com
info@immatics.com

Improving Immunity
Abstract List (001 - 022)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
001	Adams III	–	GEN1042 (DuoBody®-CD40x4-1BB) in combination with PD-1 blockade reverses T-cell exhaustion in vitro
002	Amar	–	The transcriptional landscape of tumor-infiltrated leukocytes upon OX40 agonist antibody treatment
003	Buonaguro	–	Molecular mimicry and cross-reactive CD8+ T cell responses to cancer testis antigens (CTA) and homologous microbiota-derived epitopes
004	Corgnac	–	CD8+ tumor-resident memory T cells have a pivotal role in cancer immunotherapy
005	–		Abstract has been withdrawn
006	Derré	–	Bladder immune responses upon intravesical Ty21a instillations in non-muscle invasive bladder cancer patients
007	Di Trani	–	Intra-tumoral delivery of mRNA encoding IL-12-fused to diabodies targeting CSF1R and PD-L1 exert potent anti-tumor efficacy while restraining systemic exposure to IL-12.
008	Ding	yes	A STING signaling relay from tumor cells to macrophage cells contributed to combinational chemotherapy efficacy on pancreatic ductal adenocarcinoma
009	Domingos-Pereira	–	Intravaginal Ty21a immunotherapy induces NK-mediated reduction of tumor growth and increases mice survival when combined with E7-vaccination or cisplatin/paclitaxel chemotherapy in the HPV16 TC-1 orthotopic cervical cancer model
010	Dukic	–	Metabolic underpinnings of macrophage phenotypes to modulate anti-cancer immune response
011	Fichter	–	Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers
012	Glanville	–	Restoring immune fitness with oral Salmonella Typhi ZH9 to increase efficacy of immunotherapies
013	Glauß	–	A novel chimeric oncolytic virus mediates a multifaceted cellular immune response in a syngeneic B16 melanoma model
014	Glöckner	–	Targeting the immunosuppressive tumor microenvironment with arginase-1 specific T cells
015	Gonçalves	–	Use of bispecific antibodies to improve transendothelial migration of T cells towards tumor cells
016	Hagelstein	–	An Fc-optimized fusion protein targeting NKG2DL for induction of NK cell reactivity against ovarian cancer
017	Hartmann	–	Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor control
018	Imle	–	HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking
019	Lee	–	Immunological characterization of expanded tumor-infiltrating lymphocytes in renal cell carcinoma patients
020	Lutz	–	IL-15 immunocytokines directed to CD135 and CD133 with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia
021	Mao	yes	Interleukin-1 receptor-associated kinase 3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
022	Mayr	–	Patient-derived head and neck tumor slice cultures – a versatile tool to study oncolytic virus action

Improving Immunity
Abstract List (023 - 041)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
023	Medina	yes	Phosphatidylserine exposure on exhausted CD8 T cells operates as a non-classical inhibitory molecule
024	Mehta	yes	CLN-617 is a first-in-class fusion protein that retains IL-2 and IL-12 in injected tumors and potently triggers systemic anti-tumor immunity
025	Middelburg	–	MHC-E, the ligand for checkpoint NKG2A, is also engaged by LILRB1 on myeloid cells
026	Müller	–	Genetic ablation of macrophage glucocorticoid receptor signalling restricts primary tumour growth and overcomes resistance to immune checkpoint inhibitor treatment
027	Muth	–	Continuous treatment with dexamethasone in combination with a CD19xCD3-bispecific antibody boosts CD8+T cell expansion and protects against T cell exhaustion in a long-term in vitro model.
028	Newnes	yes	Manipulating the balance of pro- and anti-inflammatory signals in the tumour microenvironment to enhance cancer control
029	Onyshchenko	–	IL-2/αIL-2 complexes massively expand systemic tumor-specific T cells and enhance abscopal responses to radiation and αPD1
030	Ormsby	–	Polymer-based antibody mimetics (iBodies) target human PD-L1 and serve as a potent immune checkpoint blocker in vitro
031	Reshef	–	ICOS immunotherapy – Towards understanding the mechanism of action
032	Schluck	yes	Density and ratio of stimulatory antibodies on immunofilaments influence ex vivo T cell expansion and phenotype
033	Schneider	–	Comprehensive characterization of bladder microenvironment in murine MB49 bladder tumor model to identify new therapeutic targets
034	Stolk	–	Arming the oncolytic adenovirus ORCA-010 with constitutively active GSK3β to overcome melanoma induced myeloid suppression
035	Suarez-Carmona	–	Immunomodulation induced by the drug conjugates 5-Fluorodeoxyuridine-alendronate and 5-Fluorodeoxyuridine-C-ethynylcytidine in human epithelial ovarian carcinoma
036	Teppert	–	Cell death-optimized 5'-triphosphate RNAs for improved tumor immunotherapy
037	Teschner	–	Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
038	van Elsas	–	The macrophage-T cell axis in the success and failure of immunotherapy
039	Verhoeven	–	Profiling immune checkpoints to identify synergistic targets for RANK inhibition in cervical cancer and exploring its potential
040	Vetillard	–	Immune checkpoint blockade activates hematopoietic stem cells and reprograms early hematopoiesis.
041	Wu	–	Development of bispecific T-cell engager-sialidase fusion proteins for cancer immunotherapy

Immunomonitoring
Abstract List (042 - 060)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
042	Berthier	–	Development of a novel standardized and fully automated functional assay to assess and monitor global T cell immune function in 4 hours
043	Bochem	–	Very high cytomegalovirus-specific antibody titers predict clinical outcome in melanoma under PD-1 treatment and associate with a late differentiated T cell profile
044	Danklmaier	–	Establishing a workflow to compare T cell receptor sequences in blood and tumor
045	De Ridder	–	Identification of novel biomarkers for long-term response on immunotherapy in non-small cell lung cancer patients
046	Enssle	–	Characterizing immunity after SARS-CoV-2 mRNA-vaccination and infection in patients with Multiple Myeloma
047	Fransen	yes	Correlation of peripheral blood immune markers with complete pathological response in a clinical trial of neoadjuvant chemoradiotherapy combined with dual immunotherapy followed by resection in locally advanced NSCLC patients.
048	Herold	–	High frequencies of peripheral Vδ1 T cells are associated with poor overall survival of melanoma patients undergoing PD-1 blockade and a late-differentiated phenotype
049	Hilker	–	Image-based deep-learning models enable accurate ELISpot experiment classification and evaluation
050	Höchst	yes	Detection of HER2-positive extracellular vesicles in plasma from breast cancer patients using spectral flow-cytometry
051	Inekci	–	Single cell multiomic profiling of the antigen-specific immune response using antigen specific dCODE Dextramer® (10x) reagents and 10x Chromium Single-Cell Analysis System
052	Krämer	–	An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
053	–	–	Abstract has been withdrawn
054	Poschke	–	Epitope-specific expansion cultures with subsequent TCR identification (ESPEC-SUIT) – a platform for efficient discovery of (tumor) antigen-reactive TCRs from both CD4 and CD8 T cells
055	Preyer	–	Using the whole spectrum - five colour EliSpot for more detailed immunomonitoring
056	Schnatbaum	–	Positive Control Peptide Pools for T cell Immune Monitoring
057	van der Heijden	–	In vitro expansion of Wilms' tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
058	van Zeeburg	yes	High dimensional analysis of peripheral blood mononuclear cells in AML patients shows a beneficial tumor reactive T-cell environment at start of treatment in patients responding to an allogenic leukemia-derived cancer vaccine (vididencel)
059	Veenstra	–	Intradermal tilsotolimod versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: interim efficacy and safety results of the randomized phase II INTRIM study.
060	Wistuba-Hamprecht	yes	High-dimensional in situ proteomics imaging to assess γδ T cells in human tissues

Cellular Therapy

Abstract List (061 - 083)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
061	Abken	–	The CAR forms individual synapses independently of the endogenous TCR, however, the TCR has crucial relevance in maintaining CAR T cell functionality.
062	Aindelis	–	Colon cancer cells treated with mastic essential oil release damage-associated molecular patterns (DAMPs) characteristic of immunogenic cell death
063	Akrami	–	Deciphering the metabolic capabilities of precursor exhausted T cells (Tpex) to identify novel immunotherapeutic approaches
064	Albinger	–	CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the anti-leukemic efficacy of primary CD33-targeting CAR-NK cells
065	Anastasopoulou	–	T cell therapy drives inter- and intraclonal loss of mutant p53 heterozygosity in cancer
066	António	–	Activation of tumor reactive lymphocytes by shingosine-1-phosphate
067	Bareke	–	Bcl-2-shRNA carrying exosomes isolated from engineered NK cells cause tumor regression in a triple negative breast cancer mouse model
068	Barnkob	–	BAFF-R-specific chimeric antigen receptor T cells are efficient against murine model of mantle-cell lymphoma
069	Berthel	–	Key chemokine network modulation enhances CAR T cell therapy effects in human solid tumor explants
070	Blumenberg	yes	Gut microbial taxa are linked to beneficial or adverse CAR T-cell immunophenotypes and outcomes in lymphoma patients treated with CD19-targeted CAR T-cells
071	Bury	–	Adoptive transfer of T cells transduced with an HLA-independent T-cell receptor against Tyrosinase-related protein 2
072	Buschow	–	Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation
073	Cadiou	–	While both improving anti-tumor reactivity, TIGIT editing preserves proliferation abilities of melanoma specific T-cells, in the difference to PD-1 editing
074	Castenmiller	–	TIL therapy as potential new therapeutic option for neuroblastoma patients
075	Chamberlain	–	Initiation of a phase I/II trial of CRISPR-Cas9-mediated PD-1-deficient tumour-infiltrating lymphocyte-based adoptive T-cell therapy in metastatic melanoma
076	Cramer	–	CD56 dim bright NK cells – what happens during ex vivo culture?
077	Crowther	–	Next-Generation, Inducible IL-7–Expressing, Tumor-Infiltrating Lymphocytes by Lentiviral Vector Genetic Modification for Clinical Application
078	Das	–	Advancing the Development of Cell-based Immunotherapies with the Measurement of Cell Avidity
079	Dzijak	–	A click chemistry approach to the alteration of cellular surfaces
080	Elias Yonezawa Ogusuku	–	Automated manufacture of dNPM1 TCR-engineered T cells for therapy
081	Foldvari	–	Systematic off-target screening of T-cell receptors prior to clinical application
082	Garcia-Garijo	–	Exploiting circulating lymphocytes and cell-free DNA as a source to develop minimally-invasive personalized T-cell therapies
083	Hammerl	yes	T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer

Cellular Therapy
Abstract List (084- 104)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
084	Heeke	–	A novel TIL therapy product enriched for CD39-CD69- CD8+ T cells
085	Höchst	–	Re-Arm NK cells in Patients with acute myeloid leukemia
086	Joaquina	–	CD37 is a safe anti-AML CAR target
087	Kehm	–	Dissection of the tumor-reactive and bystander T-cell repertoires in a murine model for pancreatic cancer
088	Kiefer	–	Combination of bispecific killer cell engagers and NKG2D-CAR effector cells for enhanced antitumor activity
089	King	–	Pre-clinical characterization of a bispecific Vγ9Vδ2-T cell engager directed against prostate specific membrane antigen
090	Kirkin	–	Generation and effector function of ALECSAT cells used for adoptive cell therapy of solid tumors depends on the presence of antigen-unloaded mature dendritic cells
091	Konishi	–	The independent role of CD8 molecule in enhancing the reactivity of T cells redirected with chimeric antigen receptor
092	Kowol	–	Blocking the CD47/SIRPα immune checkpoint enhances myeloid cell mediated killing of BCP-ALL cells by an IgA2 variant of daratumumab
093	Kurtz	–	An intrinsic radiohapten capture system for CAR T cells that reports biodistribution and function
094	Lamers	–	Stem cell derived natural killer cells exert efficient ADCC through endogenous CD16 and facilitate monoantigen-specific dual tumor targeting via engament of chimeric antigen receptor and monoclonal antibody.
095	Legscha	–	Identifying new features of T cell senescence unveils high anti-tumor activity despite impaired proliferation and disturbed metabolic activity: a new avenue for cancer immunotherapy
096	Lehander	–	Elimination of primary human acute myeloid leukemia in vivo by T-cell receptor-mediated targeting of a shared neoantigen
097	Lérias	–	Tumor – Reactive γδ TILs from patients with epithelial cancer
098	Lösch	yes	Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment
099	Marraffa	yes	T cell receptors equipped with ICOS demonstrate enhanced control of melanoma recurrence and T cell longevity upon adoptive therapy in vivo
100	Mendonça Gorgulho	–	IL-12 induces transcriptional and epigenetic programming of TIL from pancreatic cancer favoring Th1 differentiation, tissue homing and polyfunctionality
101	Meng	–	The tumor-reactive CD8+ T-cell repertoire in human pancreatic cancer as revealed by single-cell sequencing
102	Mensali	–	A novel and unexpected target antigen for CAR therapy in metastatic osteosarcoma
103	Michen	–	Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma
104	Missing	–	CAR Detection Reagents - Applications for flow cytometry, cellular enrichment, and microscopic imaging.

Cellular Therapy
Abstract List (105- 127)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
105	Modamio Chamarro	yes	Analysis of the bio-distribution and targeting efficacy of CAR T-cell therapy in a whole mouse body
106	–		Abstract has been withdrawn
107	–		Abstract has been withdrawn
108	Olivera	–	mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
109	Ozkazanc	–	Robust anti-tumor activity of CAR-engineered umbilical cord blood CD34+ progenitor cell-derived NK against B-cell leukaemia provides new prospect for cancer immunotherapy
110	Paberalė	–	Dendritic cells' role in ovarian cancer immunotherapy vaccine
111	Pardo Valencia	–	Generation of melanoma antigen-specific CD8+ T cells from induced pluripotent stem cells
112	Paret	–	A network of RNA binding proteins controls the expression of the CAR-T cells targets CD19 and CD20 in B-ALL
113	Pinto	–	Nanosystems and T cell therapy for cancer: potential applications
114	Quadflieg	–	Combining electroporation and lentiviral transduction for highly efficient gene engineering in primary CAR NK cells for cancer immunotherapy
115	Rhein	–	Human leukocyte antigen (HLA) matching of cancer patient-derived xenografts (PDX) models with immune cell-humanized mice
116	Röder	–	Modulation of the tumor microenvironment by genetically engineered CAR-NK cells
117	Rodriguez Ehrenfried	–	Identification and functional analysis of tumor-reactive CD4+ effector and regulatory T-cell subsets in human pancreatic cancer
118	Rosa do Carmo	–	Engineering the stromal compartment of solid tumors circumvents resistance to immune checkpoint blockade by sparking anti-tumor immunity
119	Rosselle	–	CellFit: T cells fit to fight cancer
120	Roth	–	Ex vivo modification of haematopoietic cell transplants in GvHD prevention: Revealing the mechanism of action of the anti-human CD4 antibody MAX.16H5 for induction of immune tolerance
121	Salem	–	Antigen-specific solutions for T Cell Therapy Development and Manufacturing.
122	Sandholzer	–	Clonotype and transcriptome analysis of adoptive TIL products allows insight into T cell behaviour to improve future processing approaches
123	Schoutrop	–	The therapeutic potential and limitations of mesothelin-directed CAR T cells for the treatment of ovarian cancer
124	Skovbakke	–	Studying the role of α2,6-linked sialic acid in human dendritic cells and the potential of genetically glycoengineered dendritic cells for cancer immunotherapy
125	Stock	–	Short amino acid linker in the extracellular antigen recognition domain of CD137-based anti-BCMA CAR for improved T cell therapy in multiple myeloma
126	Stripecke	–	A basket approach for customized off-the-shelf CAR-Target-EBV: CAR-T cells armed via genome editing against tumors associated with EBV
127	Tan	–	Machine learning-based prediction of tumor-reactive T cell receptors from tumor-infiltrating T cells

Cellular Therapy

Abstract List (128- 136)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
128	TAVȘAN	–	TGF-β1 receptor inhibitor SB-431542 inhibits proliferation of metastatic breast carcinoma cells and enhances anti-tumoral effects of Doxorubicin
129	To	–	Translating CAR-T cell therapy in the treatment of Cutaneous T cell Lymphoma
130	van den Bulk	–	Development of a personalized neoantigen specific TCR discovery platform
131	Velasco Santiago	–	Exploiting cDC1 reprogramming for TIL-based adoptive cell therapy
132	Villatoro	–	Novel combinatorial IGK-CD19 CAR efficiently and selectively targets malignant B cells.
133	Vogt	yes	Tumor microenvironment actuated GD2 CAR T cells prevent on-target off-tumor toxicities
134	Wagner	–	Capturing T cells with light: A novel strategy for the identification of myeloma-specific T cells in single cell interaction assays
135	Yildiz	–	Discovery and functional validation of high affinity Rpl18 neoantigen-specific TCRs
136	Yuste-Estevanez	–	Neo-Scan a flexible MS-immunopeptidomics approach to unbiasedly discover shared neoantigens

Therapeutic Vaccination

Abstract List (137 - 148)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
137	Affandi	–	Multiple human dendritic cells subsets express CD169 and can be targeted by ganglioside-liposomes for anti-cancer vaccination strategy
138	Bequet-Romero	–	From CIGB-247 to HEBERSaVax: The road to the clinic of a VEGF-specific active immunotherapy.
139	Boschert	–	A Vaccine Targeting The Recurrent Driver Mutation H3K27M Induces Mutation Specific T- and B-Cell Responses In Patients with Diffuse Midline Gliomas
140	C Acúrcio	–	Unlocking Pancreatic Cancer to NanoImmunotherapy
141	Cui	yes	A STING agonist potentiates a C1 lipid-based mRNA cancer vaccine through promoting TNFα secretion in dendritic cells.
142	Dietzen	–	NeoAnts – A pipeline to identify NEOantigens from AlterNaTive Splicing
143	Fant	–	The evolution of neoantigens in tumor progression in patient cases with low TMB malignancies
144	Förster	–	Establishment of a validated human papillomavirus T cell epitope repertoire map via targeted immunopeptidomics enables vaccine design with broad population coverage
145	Grassl	yes	A long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with diffuse midline glioma
146	Huijbers	–	Therapeutic vaccination against the vascular immune checkpoint extracellular vimentin – a clinical trial in client owned dogs with urothelial cancer of the bladder
147	Kessler	–	Design and ex vivo testing of hepatitis B virus-based synthetic long peptides to treat chronic infection and hepatocellular carcinoma
148	Lam	–	A retrospective analysis of risk factors associated with immune checkpoint inhibitor induced-pneumonitis in cancer patients

Therapeutic Vaccination

Abstract List (149 - 171)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
149	Lang	–	Modelling immune responses utilizing a broad range of features
150	Lindner	–	Identification and characterization of vaccine-induced neoepitope-specific T cell receptors in patients with IDH1-mutant glioma
151	Magré	–	Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients
152	Marschall	–	ODI-2001 personalized immunization platform shows antitumoral effectiveness across different syngeneic mouse tumor models.
153	Marzella	–	Applying Geometric Deep Learning to structure-based peptide-MHC binding affinity predictions
154	Meimandi Parizi	–	PANDORA: A pan-allele modeling package for peptide-MHC class I and II structures
155	Mensali	–	Glioblastoma immunotherapy: challenges and immune correlates of response
156	Michel	–	Induction of circulating antitumor specific CD8+ T cells in patients with non-small cell lung cancer treated with an allogeneic plasmacytoid dendritic-cell based cancer vaccine with or without anti-PD-1 treatment
157	Nijen Twilhaar	–	Liver tissue-resident T cell generation upon liposomal cancer vaccination
158	Notaro	–	Simultaneous gene-based delivery of tumor antigen and cytokines to liver macrophages unleash a potent immune response against liver metastases
159	Oezbek	–	An innovative LC-MS methodology for the GMP-compliant quality control of peptide vaccines in individualized immunotherapy settings
160	Olin	–	Development of a Pan-Peptide Checkpoint Inhibitor in the Treatment of Central Nervous System Tumors
161	Pace	–	Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness andtumor rejection
162	Riva	yes	NKG2A blockade oppositely impacts intra-tumoral and peripheral CD8 T cell response induced by KISIMA – VSV-GP heterologous vaccination
163	Schunke	–	Multicomponent adjuvantation of antigen-based nanocapsules using site-directed click chemistry crosslinking for the treatment of melanoma
164	Singh	–	DCOne-derived mature DCs opsonized with anti-PD-L1 antibodies as potential intratumoral immune primers.
165	Tagliamonte	–	Molecular mimicry and cancer vaccine development
166	Temme	–	Toll-like receptor 3 agonist immunoconjugates eradicates EGFRvIII-positive experimental glioma
167	van der Gracht	–	T cell inducing SLP vaccine against SARS-CoV-2 for protection of patients with spontaneous or therapy-induced B cell deficiencies
168	Van Gool	–	Real world data on individualized multimodal immunotherapy as part of first-line treatment for patients with glioblastoma multiforme
169	Wellach	–	Identification and functional characterization of HLA-restricted HPV16 E6- and E7-derived epitopes
170	Welters	yes	Phase I/II clinical trial targeting alternative shared neoantigens (TEIPP) in checkpoint-resistant non-small cell lung cancer.
171	Zottnick	–	Induction of mucosal immunity by modulation of therapeutic HPV16 vaccination approaches

New Targets & New Leads

Abstract List (172 - 192)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
172	Albieri	–	Spontaneous antigenic mimicry arises from acquired mutations in cancer giving rise to TIL responses in vitro
173	Alikhanyan	–	Bovine meat and milk factor protein expression in pancreatic ductal adenocarcinoma: implications on cancer development
174	Alten	–	Antibody therapeutic development with an integrated platform combines immunized libraries, synthetic libraries, AI/ML guided leads optimization and HT IgG production
175	Anderson	yes	Genome-scale in vivo CRISPR screens identify Erap1 as a non-classical MHC-I-dependent immunotherapy target
176	Becker	–	Identification of actionable neoepitopes for personalized cancer immunotherapy by MS-based immunopeptidomics
177	Benboubker	–	Investigation of the antitumor immune response of optimized multidrug combinations in colorectal cancer model
178	Benoot	–	Decipher novel cytotoxic T cell resistant mechanisms in lung cancer.
179	Boutemine	–	NF-kappaB c-Rel is a master regulator of CD8+ T-cell function in cancer
180	Bund	–	Link between bovine meat and milk factor protein expression and inflammation as possible cause of colorectal cancer after decades-long latency
181	Capello	yes	GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity
182	Carretero	–	Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1
183	Cecere	–	Bovine Meat and Milk Factors protein expression coincides with peritumor alveolar macrophages in lung cancer tissues
184	–		Abstract has been withdrawn
185	Dulberg	–	Colorectal cancer cells induce a unique transcriptome signature in eosinophils and primes their responses to IL-3-induced activation.
186	Flade	–	Fast and easy: isolation of functional immune cells straight from mouse spleen
187	Ford	–	Long-lasting response to anti-TIM3 immune checkpoint inhibitor therapy in acute myeloid leukemia patient with large oligoclonal T cell expansion
188	Inan	–	Application of the microbiome-based prediction test BiomeOne quantifies antibiotic, geographical and health-related effects on response to cancer immunotherapy in a large European cohort
189	Giacca	–	In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases
190	Häfele	–	Profiling pathogenicity of Bovine Meat and Milk Factors in different cancer types via analysis of high-throughput sequencing data
191	Harada	–	Tumor-associated macrophage-targeted immunotherapy by intravenous injcetion of TLR agonist-loaded, DC-SIGN-selective nanoparticles
192	Hering	–	Sphinganine membrane-anchors TLR4 adapters in macrophages to promote inflammation

New Targets & New Leads

Abstract List (193 - 216)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
193	Hoffmann	–	A new membrane protein library for the identification of novel protein/protein interactions to different immune cell populations and to discover novel modulators of phagocytosis
194	Hughes	–	Shining a light on GPR65 for cancer immunotherapy
195	Hussein	–	Immune resistance genes prevent immune rejection of pancreatic ductal adenocarcinoma (PDAC)
196	Ibn-Salem	–	Detecting somatic HLA loss from genomic and transcriptomic tumor sequencing data
197	Schiemann	–	YB-200, a novel IgG1 antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response
198	Jaworski	–	Early de-risking of IMA402 TCER® by a unique preclinical safety program
199	Jovanovic	–	Association of PD-L1 expression and autophagy in patients with ovarian cancer
200	Joyce	–	First-in-class inhibitors of ERAP1, generating cancer antigens as novel targets for MHCI-targeted therapies
201	Jure-Kunkel	–	GEN1046 (DuoBody®-PD-L1x4-1BB) reverses T-cell exhaustion in vitro
202	Kedde	–	B-Cūr: A universal discovery platform enabling the selection of stable and rare antibodies from patients to discover novel therapeutic targets.
203	Keppler	–	Novel Imidazoquinolines with improved pharmacokinetic properties
204	Krug	–	Identification of immune cell populations associated with anti-PD-1 resistance in murine melanoma using CITE-seq (cellular indexing of transcriptomes and epitopes).
205	Lang	–	splice2neo combines the effect of somatic mutations on splicing with RNA-seq support to predict tumor-specific splice junctions as neoantigen candidates
206	–	–	Abstract has been withdrawn
207	–	–	Abstract has been withdrawn
208	Melero	–	Combination therapy with GEN1042 (DuoBody®-CD40x4-1BB): safety and preliminary efficacy in advanced solid tumors
209	Metzger	–	Humanized PD-1 knock-in mice as a preclinical model for testing novel immunotherapies in combination with anti-human PD-1 therapeutics
210	Ncembu	–	Recombinant CD64-directed immunotoxin exhibits cytotoxicity and may become part of a tool set for site-specific diagnosis and treatment of acute myeloid leukemia
211	Ockfen	–	PD-L1 interactome at the immunological synapse between cytotoxic lymphocytes and tumor cells
212	Olesch	yes	BAY 2965501: A highly selective DGK-ζ inhibitor for cancer immuno-therapy with first-in-class potential
213	Ophir	yes	Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity
214	Paster	–	The immunopeptidome of paediatric high-grade osteosarcoma
215	Puig Gamez	–	Investigating membrane protein function in the anti-tumor immune response: a cross-presentation screen
216	Buonaguro	–	SARS-COV-2 antigens as a natural anti-cancer preventive immunization

New Targets & New Leads

Abstract List (217 - 228)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
217	Rubenbauer	–	Targetable T-cell epitopes in H3.3K27M altered diffuse midline gliomas
218	Sanecka-Duin	–	AI-based tools for target identification foster the generation of novel TCR hits against solid tumor antigens
219	Sax	–	SJ1 drives immune resistance in MITFlow melanomas
220	Schineis	–	Combination of a bi-specific 4-1BB x PD-L1 immune cell activator and TAA x CD3 T cell engagers enhances anti-tumor efficacy
221	Schöllhorn	–	Identification of T cell targets by immunopeptidomics of small cell lung cancer
222	Schotte	yes	Identification and development of KBA1412, a fully human, first-in-class CD9 antibody for the treatment of cancer
223	Skeltved	–	Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice
224	Stadler	–	Preclinical efficacy of an RNA-encoded T-cell engaging bispecific antibody targeting human Claudin 6
225	Tsyklauri	–	KLRK1 and IL-7R expressing CD8+ T cells: a hidden target of IL-2 immunotherapy?
226	Turqueti Neves	yes	Novel myeloid immune checkpoints identified by iOTarg, a function-based high-throughput discovery platform
227	Van den Eynde	–	CD70-directed CAR natural killer cells require IL-15 stimulation for optimal elimination of CD70+ cancer-associated fibroblasts and tumor cells in colorectal cancer and pancreatic ductal adenocarcinoma
228	Vijver	–	Collagen fragments produced in cancer mediate T cell suppression through Leukocyte-Associated Immunoglobulin-Like Receptor 1

Tumor Biology and Interaction with the Immune System

Abstract List (229 - 235)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
229	Abdulrahman	–	The immune landscape during malignant transformation of the vulva and its prognostic potential
230	Angelova	yes	Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in TRACERx
231	–	–	Abstract has been withdrawn
232	Ascic	–	In Vivo Cell Fate Reprogramming Elicits Anti-tumor Immunity
233	Banki	–	Differential infection of dendritic cell subsets by oncolytic vesicular stomatitis virus variants
234	Benvenuti	yes	Type 1 DCs drive anti-tumoral immunity to endogenous immunogenic neoantigens in lung cancer
235	Bilich	–	Combining the organoid technology with CRISPR to study immune responses to hematological premalignancies and neoplasia

Tumor Biology and Interaction with the Immune System

Abstract List (236 - 258)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
236	Biolato	–	Actin remodelling and small vesicle recruitment hinder effective anti-tumor immunity by shaping the tumor cell side of the immune synapse
237	Braband	–	Characterization of tissue-resident regulatory T cells in healthy human tissue and tumors on single-cell level
238	Caforio	–	AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK cell cytotoxicity through immune check-point modulation
239	Chavez Abiega	–	Advancing IO drug development by high content imaging of immune cell co-cultures with organoids from diverse cancer indications
240	Coelho	–	The role of IL4I1 in myeloid cells and its impact on immune control of chronic lymphocytic leukemia
241	Cremasco	–	Human 3D in vitro models for the assessment of Cancer Immunotherapy Mode of Action
242	Daniel	–	Identification of synergistic drug combinations with MEK inhibitors for the treatment of pancreatic cancer
243	de Haas	–	DC-SIGN-related function in vaccination and tumor control in a transgenic human DC-SIGN mouse-model
244	Díaz-Gómez	yes	Unravelling tumor-intrinsic resistance mechanisms to T-cell mediated cytotoxicity in pancreatic cancers
245	D'Rozario	–	Patient derived lung cancer organoids to study tumor immune interactions
246	Garcia Marquez	–	Germline homozygosity and allelic imbalance of HLA-I are common in esophago-gastric adenocarcinoma and impair the repertoire of immunogenic peptides
247	Goyvaerts	–	Single-cell analysis of the bone marrow niche from lung tumor bearing mice reveals cell subset specific myelopoiesis perturbing cues
248	Griffioen	–	Improving immunotherapy by overcoming tumor endothelial cell anergy
249	Guo	–	A tryptophan metabolite activates tumor immunogenicity to potentiate adoptive T cell-based cancer immunotherapy
250	Hagen	–	Patterns of immune evasion in primary and metastatic colorectal cancer
251	Haß	–	The role of IκB Kinase epsilon in malignant melanoma
252	Hatami	–	Establishment of a mixed tumor model to study the therapeutic potential of an immune-modulatory cargo-expressing oncolytic virus
253	Heiduk	–	PD-1 and TIGIT expression delineate distinct functional T cell subsets with prognostic relevance in pancreatic cancer
254	Hirigoyen	–	Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and increase their immunogenicity
255	Holtkotte	–	Three-dimensional (3D) bioprinting: new models in cancer immunotherapy
256	Kanagasabesan	–	Can we predict which TIL products will react against NSCLC tumours based on the immuneinfiltrates?
257	Khinvasara	–	Single-cell profiling and validation of tumor-specific TCR repertoires to study immune escape in Small cell lung cancer (SCLC) patients
258	Kolb	–	Melanoma-derived IκBζ as a key modulator of the tumor microenvironment and therapy response

Tumor Biology and Interaction with the Immune System

Abstract List (259 - 281)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
259	Kordaß	–	Targeting of the immune suppressive tumor milieu by pan-functional miRNAs
260	Kosiol	–	Overcoming immune checkpoint therapy resistance by G-quadruplex stabilization
261	Kraemer	–	The immunopeptidome landscape associated with T cell infiltration, inflammation and immune-editing in lung cancer
262	Lehmann	–	Functional role of tumor-specific B-cell responses in preclinical models of immune checkpoint therapy
263	–	–	Abstract has been withdrawn
264	Lopez Carranza	–	Enhancing Predictive Performance of pMHC class I Presentation Models through Multi-Allelic Data Integration Techniques and Comparative Analysis of Architectural Choices
265	Lutz	–	IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
266	Marx	–	Tumor cell-secreted chemokines shape the immunosuppressive myeloid compartment in PDAC models
267	Oelgarth	–	Dissecting the phenotype, clonality and function of tumor-reactive NK cells in response to immunotherapy
268	Okada	yes	Glioma-induced neuronal remodeling promotes regional immunosuppression
269	Pöchmann	–	Immunomodulation induced by Interleukin-1 inhibition activates T cells and dendritic cells in colorectal cancer
270	–	–	Abstract has been withdrawn
271	Quatannens	–	Mapping the TIGIT Axis in Pancreatic Cancer: Insights for Immunotherapy Targets.
272	Roelands	–	An Atlas and Compass of Immune-Cancer-Microbiome interactions in colon cancer
273	Rupp	–	Humanized mouse models for the preclinical evaluation of novel cancer immunotherapy options.
274	Schork	–	Subtype-specific immune interactions in Small Cell Lung Cancer indicate distinct vulnerabilites to immunotherapeutic approaches
275	Schwarz	–	An unsurmountable immunologic barrier? A detailed view on the interaction of hypermutated colon cancer with autologous T cells
276	–	–	Abstract has been withdrawn
277	Seiffert	–	Single-cell omics analyses identify the TIM-3 ligand Galectin-9 as novel immunotherapy target for chronic lymphocytic leukemia
278	Staufenberg	–	Tumor – associated inflammation in patients with advanced and relapsing hypopharyngeal carcinoma
279	–	–	Abstract has been withdrawn
280	Thomas	–	Actin cytoskeleton remodeling at the tumor cell side of the immunological synapse mediates multiple resistance mechanisms against cytotoxic lymphocytes
281	Tigu	–	Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukemia

Tumor Biology and Interaction with the Immune System

Abstract List (282 - 297)

NO.:	PRESENTER:	SHORT TALK:	TITLE:
282	Tirapu	–	Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics
283	Torres Fernández	–	Enhancing Neoantigen Expression in Small Cell Lung Cancer via Inhibition of the Nonsense-Mediated Decay Pathway
284	Tran	–	PBRM1 loss in clear cell renal cell carcinoma leads to a proangiogenic phenotype via increased CXCL5 secretion that can be selectively inhibited by CXCR2 inhibition.
285	van Beijnum	–	Extracellular vimentin is a suppressive vascular immune checkpoint
286	van der Heijden	–	Evaluating the therapeutic efficacy of targeting crucial metabolic pathways in glioblastoma in combination with anti-PD-1 in vivo
287	van Oost	–	Decoding the immunogenomic determinants of immunotherapy and radiotherapy response in soft tissue sarcomas
288	Verhezen	–	Natural killer cell metabolism and cytotoxicity are impaired by the hypoxic tumor microenvironment
289	Verkerk	yes	Expression of neolacto-series glycosphingolipids by tumors impairs the anti-tumor function of innate and adaptive immune responses.
290	Volkmar	–	Enhanced mutanome analysis towards the isolation of neoepitope-reactive T cell receptors for personalized immunotherapy of pancreatic cancer
291	Wennhold	–	Organization, function and gene expression of tertiary lymphoid structures in pancreatic cancer resembles lymphoid follicles in secondary lymphoid organs and their abundance is related to superior survival
292	Werner	–	A rapid-processing ex vivo pipeline to unravel the immune phenotype of obesity-related hepatocellular carcinoma reveals impairment of MAIT cells
293	Wiecken	–	Melanoma cell intrinsic LAG-3 expression correlates with metastasis stage and might indicate resistance to anti-PD-1 monotherapy
294	Wölfel	–	Incorporation of TRDV segments into TCR alpha chains
295	–	–	Abstract has been withdrawn
296	You	–	Interleukin-38 promotes colon carcinogenesis via inhibiting T cell-mediated intestinal inflammation
297	Zens	yes	Charting the tumor-reactive T-cell repertoire in DNA damage repair (DDR) deficient pancreatic cancer towards development of personalized T-cell therapy

IMPRINT

POSTAL ADDRESS

Association for Cancer Immunotherapy CIMT e.V.
Göttelmannstraße 17
55130 Mainz, Germany
Telephone: +49 (0) 151 - 53 222 559
Website: www.cimt.eu
E-Mail: office@cimt.eu

REGISTER OF ASSOCIATIONS

Amtsgericht Mainz: VR 3783

CONCEPT AND DESIGN

LABOR – Agentur für moderne Kommunikation GmbH
Fischtorplatz 21
55116 Mainz, Germany
Telephone: +49 (0) 6131 - 30 46 76 2
Website: www.labor.digital

PHOTOS

Andrea Enderlein
Isabelle Niefer